Tara Renée Heitner Hansen
Fondatore presso Abarceo AB
Profilo
Tara Renée Heitner Hansen is the founder of Heitner Biopharm Consultation (founded in 2014) and Abarceo AB (founded in 2017), where she holds the title of Chief Executive Officer & Director.
She currently holds director positions at TikoMed AB, Nordic Pharma Licensing Group, and Bainan Biotech.
Her former positions include Chief Executive Officer at iSD Immunotech ApS (2018-2021) and Chief Executive Officer at Cyxone AB (2020-2022).
Dr. Heitner Hansen holds a doctorate from McGill University and an MBA from the Technical University of Denmark.
Posizioni attive di Tara Renée Heitner Hansen
| Società | Posizione | Inizio |
|---|---|---|
Abarceo AB
 Abarceo AB Miscellaneous Commercial ServicesCommercial Services Abarceo AB develops novel therapeutics for type-2 diabetes. It identifies a novel diabetes target located on beta cells and a novel mechanism of action enabling a therapeutic treatment to revert beta cells from dysfunctional to functional, preserving beta cell function and allowing patients to produce insulin naturally. The company was founded by Tara Heitner, Claes Wollheim, and Albert Salehi in December 2017 and is headquartered in Malmo, Sweden. | Fondatore | 01/12/2017 |
| Nordic Pharma Licensing Group | Direttore/Membro del Consiglio | - |
| Bainan Biotech | Direttore/Membro del Consiglio | - |
TikoMed AB
 TikoMed AB Pharmaceuticals: MajorHealth Technology TikoMed AB is a Swedish pharmaceutical company that develops pharmaceutical products. The private company is based in Viken, Sweden. The company was founded by Adam Bruce, Lars Bruce. Anders Kristensson has been the CEO of the company since 2018. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Tara Renée Heitner Hansen
| Società | Posizione | Fine |
|---|---|---|
| CYXONE AB | Amministratore Delegato | 20/06/2022 |
iSD Immunotech ApS
 iSD Immunotech ApS BiotechnologyHealth Technology iSD Immunotech ApS develops immunoregulatory peptides and proteins. It conducts research and development on immunoregulatory peptides for possible applications and commercialization. The company was founded by Peter Samuel Wulff, Shervin Bahrami, Finn Skou Pedersen, Mogens Ryttergård Duch, Lars Jørgen Østergaard, Martin Tolstrup, and Martin Thygesen on August 9, 2007 and is headquartered in Aarhus, Denmark. | Amministratore Delegato | - |
| Heitner Biopharm Consultation | Fondatore | - |
Formazione di Tara Renée Heitner Hansen
| McGill University | Doctorate Degree |
| Technical University of Denmark | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| CYXONE AB | Health Technology |
| Aziende private | 6 |
|---|---|
TikoMed AB
TikoMed AB Pharmaceuticals: MajorHealth Technology TikoMed AB is a Swedish pharmaceutical company that develops pharmaceutical products. The private company is based in Viken, Sweden. The company was founded by Adam Bruce, Lars Bruce. Anders Kristensson has been the CEO of the company since 2018. | Health Technology |
iSD Immunotech ApS
iSD Immunotech ApS BiotechnologyHealth Technology iSD Immunotech ApS develops immunoregulatory peptides and proteins. It conducts research and development on immunoregulatory peptides for possible applications and commercialization. The company was founded by Peter Samuel Wulff, Shervin Bahrami, Finn Skou Pedersen, Mogens Ryttergård Duch, Lars Jørgen Østergaard, Martin Tolstrup, and Martin Thygesen on August 9, 2007 and is headquartered in Aarhus, Denmark. | Health Technology |
| Nordic Pharma Licensing Group | |
Abarceo AB
Abarceo AB Miscellaneous Commercial ServicesCommercial Services Abarceo AB develops novel therapeutics for type-2 diabetes. It identifies a novel diabetes target located on beta cells and a novel mechanism of action enabling a therapeutic treatment to revert beta cells from dysfunctional to functional, preserving beta cell function and allowing patients to produce insulin naturally. The company was founded by Tara Heitner, Claes Wollheim, and Albert Salehi in December 2017 and is headquartered in Malmo, Sweden. | Commercial Services |
| Heitner Biopharm Consultation | |
| Bainan Biotech |
- Borsa valori
- Insiders
- Tara Renée Heitner Hansen
